Research ExplorerPublicationsDocetaxel combined with irinotecan or 5-fluorouracil in pati...

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

Standard

Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. / Roy, A; Cunningham, D; Hawkins, R; Sörbye, H; Adenis, A; Barcelo, J-R; Lopez-Vivanco, G; Adler, G; Canon, J-L; Lofts, F; Castanon, C; Fonseca, E; Rixe, O; Aparicio, J; Cassinello, J; Nicolson, M; Mousseau, M; Schalhorn, A; D'Hondt, L; Kerger, J; Hossfeld, Dieter; Garcia Giron, C; Rodriguez, R; Schoffski, P; Misset, J-L.

In: BRIT J CANCER, Vol. 107, No. 3, 3, 2012, p. 435-441.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Roy, A, Cunningham, D, Hawkins, R, Sörbye, H, Adenis, A, Barcelo, J-R, Lopez-Vivanco, G, Adler, G, Canon, J-L, Lofts, F, Castanon, C, Fonseca, E, Rixe, O, Aparicio, J, Cassinello, J, Nicolson, M, Mousseau, M, Schalhorn, A, D'Hondt, L, Kerger, J, Hossfeld, D, Garcia Giron, C, Rodriguez, R, Schoffski, P & Misset, J-L 2012, 'Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.', BRIT J CANCER, vol. 107, no. 3, 3, pp. 435-441. <http://www.ncbi.nlm.nih.gov/pubmed/22767144?dopt=Citation>

APA

Roy, A., Cunningham, D., Hawkins, R., Sörbye, H., Adenis, A., Barcelo, J-R., Lopez-Vivanco, G., Adler, G., Canon, J-L., Lofts, F., Castanon, C., Fonseca, E., Rixe, O., Aparicio, J., Cassinello, J., Nicolson, M., Mousseau, M., Schalhorn, A., D'Hondt, L., ... Misset, J-L. (2012). Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. BRIT J CANCER, 107(3), 435-441. [3]. http://www.ncbi.nlm.nih.gov/pubmed/22767144?dopt=Citation

Vancouver

Roy A, Cunningham D, Hawkins R, Sörbye H, Adenis A, Barcelo J-R et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. BRIT J CANCER. 2012;107(3):435-441. 3.

Bibtex

@article{6c23125231d44d55a3c7a0b89d3f12e5,
title = "Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.",
abstract = "Docetaxel and irinotecan chemotherapy have shown good efficacy in the treatment of advanced oesophago-gastric cancer. This randomised phase II study evaluated the efficacy and toxicity profile of two non-platinum docetaxel-based doublet regimens in advanced oesophago-gastric cancer.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Disease Progression, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Taxoids/administration & dosage, Fluorouracil/administration & dosage, Camptothecin/administration & dosage/analogs & derivatives, Esophageal Neoplasms/*drug therapy, Stomach Neoplasms/*drug therapy, Adult, Humans, Male, Aged, Female, Middle Aged, Disease Progression, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Taxoids/administration & dosage, Fluorouracil/administration & dosage, Camptothecin/administration & dosage/analogs & derivatives, Esophageal Neoplasms/*drug therapy, Stomach Neoplasms/*drug therapy",
author = "A Roy and D Cunningham and R Hawkins and H S{\"o}rbye and A Adenis and J-R Barcelo and G Lopez-Vivanco and G Adler and J-L Canon and F Lofts and C Castanon and E Fonseca and O Rixe and J Aparicio and J Cassinello and M Nicolson and M Mousseau and A Schalhorn and L D'Hondt and J Kerger and Dieter Hossfeld and {Garcia Giron}, C and R Rodriguez and P Schoffski and J-L Misset",
year = "2012",
language = "English",
volume = "107",
pages = "435--441",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "3",

}

RIS

TY - JOUR

T1 - Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.

AU - Roy, A

AU - Cunningham, D

AU - Hawkins, R

AU - Sörbye, H

AU - Adenis, A

AU - Barcelo, J-R

AU - Lopez-Vivanco, G

AU - Adler, G

AU - Canon, J-L

AU - Lofts, F

AU - Castanon, C

AU - Fonseca, E

AU - Rixe, O

AU - Aparicio, J

AU - Cassinello, J

AU - Nicolson, M

AU - Mousseau, M

AU - Schalhorn, A

AU - D'Hondt, L

AU - Kerger, J

AU - Hossfeld, Dieter

AU - Garcia Giron, C

AU - Rodriguez, R

AU - Schoffski, P

AU - Misset, J-L

PY - 2012

Y1 - 2012

N2 - Docetaxel and irinotecan chemotherapy have shown good efficacy in the treatment of advanced oesophago-gastric cancer. This randomised phase II study evaluated the efficacy and toxicity profile of two non-platinum docetaxel-based doublet regimens in advanced oesophago-gastric cancer.

AB - Docetaxel and irinotecan chemotherapy have shown good efficacy in the treatment of advanced oesophago-gastric cancer. This randomised phase II study evaluated the efficacy and toxicity profile of two non-platinum docetaxel-based doublet regimens in advanced oesophago-gastric cancer.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Disease Progression

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Taxoids/administration & dosage

KW - Fluorouracil/administration & dosage

KW - Camptothecin/administration & dosage/analogs & derivatives

KW - Esophageal Neoplasms/drug therapy

KW - Stomach Neoplasms/drug therapy

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Disease Progression

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - Taxoids/administration & dosage

KW - Fluorouracil/administration & dosage

KW - Camptothecin/administration & dosage/analogs & derivatives

KW - Esophageal Neoplasms/drug therapy

KW - Stomach Neoplasms/drug therapy

M3 - SCORING: Journal article

VL - 107

SP - 435

EP - 441

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 3

M1 - 3

ER -